Workflow
睿昂基因(688217) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥54,738,007.28, a decrease of 14.72% compared to ¥64,188,221.36 in the same period last year[3] - Net profit attributable to shareholders increased significantly by 529.26% to ¥3,355,013.27 from ¥533,165.07 year-on-year[3] - Basic earnings per share rose to ¥0.06, reflecting a 500% increase from ¥0.01 in the previous year[4] - Total operating costs for Q1 2025 were CNY 55,633,595.22, down from CNY 64,568,301.80 in Q1 2024, reflecting a reduction of 13.8%[22] - Net profit for Q1 2025 was CNY 1,841,429.31, compared to a net loss of CNY 1,437,353.69 in Q1 2024, indicating a significant turnaround[23] - The company reported an operating profit of CNY 1,797,016.26, compared to an operating loss of CNY 2,213,823.14 in the previous year[22] Research and Development - Research and development (R&D) expenses totaled ¥10,988,068.94, down 32.99% from ¥16,398,202.66, with R&D expenses accounting for 20.07% of revenue, a decrease of 5.48 percentage points[4] - Research and development expenses for Q1 2025 were CNY 10,988,068.94, down from CNY 16,398,202.66 in Q1 2024, a decrease of 32.5%[22] Cash Flow and Assets - The net cash flow from operating activities was ¥10,538,321.54, a decline of 8.51% from ¥11,518,866.49 in the previous year[3] - As of March 31, 2025, the company's cash and cash equivalents amounted to ¥111,923,118.97, a decrease from ¥139,151,947.97 on December 31, 2024, representing a decline of approximately 20%[17] - The total current assets as of March 31, 2025, were ¥471,364,891.50, slightly up from ¥470,136,956.05 at the end of 2024[17] - The company's total financial assets increased to ¥112,006,062.48 as of March 31, 2025, from ¥93,526,046.51 at the end of 2024, marking a growth of approximately 19.67%[17] - The cash and cash equivalents at the end of Q1 2025 stood at $108,586,964.85, down from $145,047,025.93 at the end of Q1 2024, a decrease of 25.1%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,990[11] - The largest shareholder, Xiong Hui, holds 10,176,397 shares, representing 18.22% of the total shares[11] - The company completed a share buyback of 669,621 shares, representing 1.20% of the total share capital, with a total expenditure of ¥17,021,747.99[15] Legal and Management Changes - The company announced a change in its management structure due to legal issues involving key personnel, with a new acting representative appointed[14] - The company is under investigation for illegal activities involving its key executives, which may impact future operations and governance[14] Liabilities and Equity - Total liabilities decreased to CNY 54,619,456.99 from CNY 65,057,131.21, a reduction of approximately 16.5%[19] - The company's equity increased to CNY 922,485,901.89 from CNY 920,644,472.58, showing a slight growth[19] Inventory and Accounts Receivable - The company reported accounts receivable of ¥167,694,943.18 as of March 31, 2025, compared to ¥165,928,041.07 at the end of 2024, indicating a slight increase[17] - Inventory as of March 31, 2025, was ¥45,158,971.12, up from ¥43,400,196.20 at the end of 2024, reflecting a growth of approximately 4.05%[17] Exchange Rate Impact - The company experienced a negative impact of $751,726.51 from exchange rate fluctuations on cash and cash equivalents in Q1 2025[27]